Hainan-Hong Kong Cultural Tourism Integration Upgrades “One-Trip, Multiple-Stops” Travel Experience in China

September 5, 2025

Source: Media Outreach

HONG KONG SAR – Media OutReach Newswire – 5 September 2025 – The Hainan Free Trade Port Tourism and Culture (Hong Kong) Series Promotion Events will be held from September 7 to 11 at Hong Kong’s K11 Art Mall, marking a new chapter of tropical island tourism in China for visitors from Hong Kong and beyond.

The Hainan Free Trade Port Tourism and Culture (Hong Kong) Series Promotion Events will be held from September 7 to 11 at Hong Kong’s K11 Art Mall.

With its extensive global flight network, Hong Kong welcomes tens of millions of international tourists annually. Just across the strait, Hainan is also one of China’s most popular tourist destinations. The two regions share geographical proximity, cultural similarities, and close business ties, creating a strong foundation and vast potential for collaboration.

In recent years, tourism and cultural exchanges between Hainan and Hong Kong have flourished. A growing number of residents and tourists frequently travel between the two destinations, fostering mutual learning and cooperation in the tourism sector. In April, tourism associations from both sides signed a strategic agreement to jointly develop “one-trip, multiple-stops” itineraries, offering differentiated and complementary high-end tourism experiences that greatly enrich trips for international visitors.

Leveraging Hong Kong’s role as a “super connector,” Hainan has increased flight frequency between Hong Kong and Haikou/Sanya, enabling seamless travel from the “Pearl of the Orient” to “Sunshine Hainan” and creating a “one-hour tourism circle” for global travelers. According to the latest data from the Department of Tourism, Culture, Radio, Television and Sports of Hainan Province, from January to July, over 85,000 tourists entered Hainan from Hong Kong, a year-on-year increase of 28.8%.

The upcoming promotion event will showcase Hainan’s cultural and tourism features through diverse formats such as “imaging + intangible heritage + food + performances.” Over 80 finely curated photographs will display the authentic, dynamic, and vibrant essence of Hainan, while nearly 200 exhibits will highlight world-class, national, and provincial intangible cultural heritage items including Li brocade, coconut carvings, Miao embroidery, and bamboo weaving. More than 10 interactive activities and performances, such as martial arts demonstrations, folk singing and dancing, and artistic nail art, will emphasize the innovative reinterpretation of Hainan’s traditional culture.

Furthermore, Hainan’s visa-free policy for citizens from 86 countries, 144-hour visa-free entry for foreign tour groups from Hong Kong and Macao, and 240-hour transit visa exemption provide favorable conditions and broad possibilities for future cooperation across various fields. Wang Yuechuan, Director of the International and Hong Kong, Macao, and Taiwan Market Promotion Office of the Department of Tourism, Culture, Radio, Television and Sports of Hainan Province, stated: “We are actively collaborating with major Hong Kong enterprises to develop international performances, art exhibitions, cultural tourism, and broadcasting and film projects. Additionally, we are promoting exchanges in more than nine sports events including martial arts, dragon boat racing, and golf.”

Hashtag: #Hainan

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

China’s first independent university run by a foreign university makes “Study in Hainan” more appealing

MIL OSI

September 5, 2025

Source: Media Outreach

DANZHOU, CHINA – Media OutReach Newswire – 5 September 2025 – Recently, the permanent campus of Hainan Bielefeld University of Applied Sciences (BiUH), China’s first independent university run by an overseas higher education institution, was opened in Yangpu, Hainan Free Trade Port, more than 700 teachers and students started a new learning journey.

China’s first independent university run by a foreign university makes “Study in Hainan” more appealing

According to Judith Peltz, vice president of BiUH, the “practice-integrated” educational model of the Hochschule Bielefeld – University of Applied Sciences and Arts (HSBI) is fully utilized, classes are taught in English, German courses are offered, and a multilingual learning environment (i.e., Chinese, English, and German) is fostered. At present, four undergraduate majors are available, namely computer science, digital technologies, industrial engineering, and logistics engineering.

“The modern teaching environment of the new campus provides us with ideal learning conditions, and I am looking forward to starting my university life here.” Jiang Yuhan, a logistics engineering freshman enrolled in 2025, said.

The first phase of the permanent campus covers an area of about 20 hectares, costs an investment of 1.04 billion yuan, and can accommodate at least 2,500 students. Facilities include welcome center, public teaching building, experimental building, student center, student dormitory, teacher apartment, sports field, etc. The second phase, scheduled to be completed in 2029, will accommodate more than 12,000 students.

China’s first independent university run by a foreign university makes “Study in Hainan” more appealing

BiUH has signed strategic cooperation agreements with 10 well-known Chinese and foreign enterprises, including Weidmüller, ZF, TRUMPF (China), and China Mobile Hainan Branch, so that students can embrace career opportunities around the world.

“Our philosophy is ‘doing by learning, learning by doing,’ which not only creates connection between academia and industry but also allows education, talent training, and industrial development to be well integrated in Hainan.” Judith Peltz expressed that BiUH will leverage the high-quality educational resources of China and Germany to become a top-tier application-oriented university in the Asia-Pacific region or even in the world.

In fact, Hainan is building momentum in the “Study in Hainan” campaign, cultivating an international exchange gateway facing the Pacific and Indian Oceans, providing a new platform for cooperation with the “Belt and Road” countries, and playing an increasingly important role in China’s education opening up.

Hashtag: #BiUH

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

BGY Fruits’s Global Supply Chain Strategy: Advancing B2B Operations at Home and Abroad, and Actively Building Category Brand Subsidiaries

MIL OSI

September 5, 2025

Source: Media Outreach

SHENZHEN, CHINA – Media OutReach Newswire – 5 September 2025 – On September 3, ASIA FRUIT LOGISTICA opened at AsiaWorld-Expo in Hong Kong. BGY Fruits, China’s leading fruit retail chain, participated alongside its subsidiary Jin Chengtai, continuing its annual presence at the event. Through consistent participation, BGY Fruits showcases its strengths in supply chain integration and brand development to global partners and potential clients—further advancing its strategy of “sourcing globally, selling globally.”

Since beginning its overseas fruit sourcing in 2012, BGY Fruits has established direct procurement partnerships with over 800 premium fruit farms across 26 countries, covering nearly 1,000 fruit varieties. This extensive global sourcing has significantly enriched the domestic fruit supply and effectively filled seasonal gaps in the local market.

In recent years, the fruit supply landscape has undergone significant structural adjustments. Domestic alternatives to imported fruits—such as blueberries, durians, and passion fruits—have become increasingly prominent. At the same time, recognition of Chinese-grown fruits in international markets continues to rise, driving ongoing optimization in import and export structures.

In response to these market trends, BGY Fruits established its International Export Division to promote high-quality fruits sourced from both domestic and international origins to overseas markets, expanding and strengthening its B2B export operations. Signature products such as Liangzhi apples, Naihuang apricots, and the company’s exclusive variety of fresh purple passion fruit (Jindu No. 3) have already been introduced and are selling well in several Southeast Asian countries.

BGY Fruits’s subsidiary, Haiyang Jin Chengtai, has consistently exported premium Chinese fruits—including apples, pears, and citrus—to Hong Kong, Southeast Asia, and North America, allowing global consumers to enjoy the best of China’s fruit harvests. According to a company representative, Jin Chengtai’s export sales reached nearly RMB 300 million in 2024.

Zhu Qidong, Executive Vice President of BGY Fruits Group, Chief Supply Chain Officer, President of the B2B and International Business Division, and President of the Category Brand Division, revealed that the domestic B2B business has been a key strategic focus for BGY Fruits in 2024. Leveraging its core strength in high-quality fruit supply chain management, the company has significantly expanded into supermarkets, emerging retail channels, and large-scale distribution markets.

In addition, BGY Fruits has collaborated with leading domestic enterprises, provincial-level trade unions, and key strategic partners to jointly develop innovative fruit products and diversify its category offerings. The company has also engaged in fruit contract processing services for fresh food enterprises and launched digital fruit gift cards for online distribution.

These initiatives have driven strong growth in BGY Fruits’s domestic B2B segment. From January to July alone, wholesale business sales reached RMB 522 million.

Brand development is essential to the long-term growth of the fruit industry. In addition to building a competitive retail brand, BGY Fruits is actively advancing its category brand strategy. At the exhibition, Zhu Qidong noted that BGY Fruits has established a dedicated Category Brand Division to lead this effort. By taking an organized and systematic approach, the company aims to integrate resources across the value chain and ensure the effective execution of its category branding strategy.

Currently, BGY Fruits is leveraging its ecosystem partnerships to establish specialized companies focused on specific fruit categories, including apples, watermelons, and pineapples. In the future, this model will be replicated to build category-brand companies for imported fruits as well.

Hashtag: #BGYFruits

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease

MIL OSI

September 5, 2025

Source: Media Outreach

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.¹
In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisations in infants by 82.7% (95% CI: 67.8 to 91.5; p<0,0001) through six months (180 days). ^{2, 3}
Administration can be timed during the first year of life to protect from birth, or as early as possible.

SINGAPORE – Media OutReach Newswire – 5 September 2025 – The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca’s BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Globally, around 2 in 3 babies will catch RSV before their first birthday⁴ and it remains the most common cause of lower respiratory tract disease, including bronchiolitis and pneumonia, in infants⁵. RSV is also a leading cause of hospitalisation among infants in Singapore, with most cases occurring in otherwise healthy, full-term babies. Each year, approximately 1,804 children under 29 months are hospitalised due to RSV-related illness^6-10.

A panel of leading paediatricians in Singapore recently published an expert consensus, underscoring the urgent need for RSV protection in all infants. They concur that nirsevimab is key to alleviating the RSV burden on the healthcare system and recommend that immunisation be considered for all infants under the National Immunisation Programme in Singapore.¹¹

Zainab Sadat, Head of Vaccines, Sanofi Southeast Asia & India

“Today, Singapore joins other countries worldwide where an innovative immunisation solution is now available to protect all infants against RSV. The approval of BEYFORTUS marks a critical step towards giving parents the ability to protect their babies during their first year of life, when they are most vulnerable to severe RSV disease. We are committed to working with stakeholders across the RSV care continuum to ensure seamless implementation and broad availability of this innovative preventive solution — because every baby needs protection. Our goal is simple: to help parents protect their babies, and give them peace of mind.”

The approval was based on results from the extensive BEYFORTUS clinical development programme spanning three pivotal late-stage clinical trials. Across all clinical endpoints, a single dose of BEYFORTUS demonstrated high and consistent efficacy against RSV disease sustained for at least five months. BEYFORTUS was well tolerated with a favourable safety profile that was consistent across all clinical trials. The overall rates of adverse events were comparable between BEYFORTUS and placebo and the majority of adverse events were mild or moderate in severity.

In temperate countries, the single administration of BEYFORTUS was developed to correspond with the beginning of the RSV season for babies born prior to the season or at birth for those born during the RSV season. In clinical trials, BEYFORTUS helped prevent RSV disease requiring medical care in all infant populations studied, including those born healthy, at term or preterm, or with specific health conditions that make them vulnerable to severe RSV disease. RSV disease requiring medical care included physician office, urgent care, emergency room visits and hospitalisations.

About RSV

RSV is a highly contagious virus that can lead to serious respiratory illness for infants.⁵ It is a leading cause of hospitalisation in all infants, with most hospitalisations for RSV occurring in otherwise healthy infants born at term^6-10. Two out of three infants are infected with RSV during their first year of life and almost all children are infected by their second birthday⁴. Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalisations, and it was estimated that there were 26,300 in-hospital deaths of children younger than five years¹². RSV-related direct medical costs, globally — including hospital, outpatient and follow-up care — were estimated at €4.82 billion in 2017¹³.

About BEYFORTUS

BEYFORTUS (nirsevimab) is the first immunisation designed for all newborns and infants for protection against RSV disease through their first RSV season, including for those born healthy at term or preterm, or with specific health conditions. It is also indicated for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

As a long-acting antibody provided directly to newborns and infants as a single dose, BEYFORTUS offers rapid protection to help prevent lower respiratory tract disease caused by RSV without requiring activation of the immune system. BEYFORTUS administration can be timed to coincide with the RSV season.

BEYFORTUS has been approved for use in the European Union, the US, China, Japan, and many other countries around the world. Special designations to facilitate expedited development of BEYFORTUS were granted by several regulatory agencies, including Breakthrough Therapy Designation and Priority Review designation by The China Center for Drug Evaluation under the National Medical Products Administration; Breakthrough Therapy Designation and Fast Track Designation from the US Food and Drug Administration; access granted to the European Medicines Agency (EMA) PRIority MEdicines (PRIME) scheme and EMA accelerated assessment; Promising Innovative Medicine designation by the UK Medicines and Healthcare products Regulatory Agency; and BEYFORTUS has been named “a medicine for prioritized development” under the Project for Drug Selection to Promote New Drug Development in Pediatrics by the Japan Agency for Medical Research and Development.

About the clinical trials

The Phase 2b trial¹⁴ was a randomised, placebo-controlled trial designed to measure the efficacy of BEYFORTUS against medically attended lower respiratory tract disease (LRTD) caused by RSV through 150 days post-dose in healthy preterm infants of 29 to less than 35 weeks’ gestation (n=1,453). Infants were randomised (2:1) to receive a single 50 mg intramuscular injection of BEYFORTUS (n=969) or placebo (n=484) regardless of weight at the RSV season start. The primary endpoint was met, significantly reducing the incidence of medically attended RSV LRTD by 70.1% (95% CI: 52.3, 81.2; P<0.001) compared to placebo. In a prespecified secondary endpoint, BEYFORTUS reduced medically attended RSV LRTD with hospitalisation by 78.4% (95% CI 51.9, 90.3) versus placebo.

The BEYFORTUS dosing regimen was determined based on further exploration of the Phase 2b data and was used in subsequent trials as a single 50 mg dose for infants who weigh less than 5 kg, or a single 100 mg dose for those who weigh 5 kg or greater. A post-hoc analysis of the Phase 2b study that applied the recommended 50 mg dose in a subgroup of infants weighing less than 5 kg showed the efficacy of BEYFORTUS against medically attended RSV LRTD and medically attended RSV LRTD with hospitalisation was 86.2% (95% CI 68.0, 94.0) and 86.5% (95% CI 53.5, 96.1), respectively.

The Phase 3 MELODY trial¹⁵ was a randomised, double-blind, placebo-controlled trial conducted across 21 countries designed to determine the safety and efficacy of BEYFORTUS against medically attended LRTD caused by RSV in healthy term and late preterm infants (35 weeks gestational age or greater) entering their first RSV season, including efficacy against severe disease such as hospitalisation, through 150 days after dosing. The primary endpoint was met, reducing the incidence of medically attended RSV LRTD by 74.5% (95% CI 49.6, 87.1; P<0.001) compared to placebo. The efficacy of BEYFORTUS against the secondary endpoint of hospitalisation was 62.1% (-8.6, 86.8). A pre-specified pooled analysis of the Phase 3 MELODY trial showed the efficacy of BEYFORTUS against medically attended RSV LRTD and medically attended RSV LRTD with hospitalisation was 79.5% (95% CI 65.9, 87.7; P<0.0001) and 77.3% (95% CI 50.3, 89.7; P<0.001), respectively.

MEDLEY was a Phase 2/3¹⁶, randomised, double-blind, palivizumab-controlled trial with the primary objective of assessing safety and tolerability for BEYFORTUS in preterm infants of less than 35 weeks’ gestational age and infants with congenital heart disease (CHD) and/or chronic lung disease (CLD) of prematurity eligible to receive palivizumab. Between July 2019 and May 2021, a total of 925 infants at higher risk for severe RSV disease entering their first RSV season were randomised to receive BEYFORTUS or palivizumab. Safety was assessed by monitoring the occurrence of treatment emergent adverse events (TEAEs) and treatment emergent severe adverse events (TESAEs) through 360 days post-dose. Serum levels of BEYFORTUS following dosing (on day 151) in this trial were comparable with those observed in the Phase 3 MELODY trial, indicating similar protection in this population to that in healthy term and late preterm infants is likely.

BEYFORTUS was well tolerated with a favourable safety profile that was similar to palivizumab in the MEDLEY Phase 2/3 trial and consistent with the safety profile in healthy term and preterm infants compared to placebo across the MELODY and Phase 2b trials. The overall rates of adverse events were comparable between BEYFORTUS and placebo and the majority of adverse events were mild or moderate in severity.

The results of MELODY, Phase 2/3 MEDLEY and the Phase 2b trials illustrate that BEYFORTUS helped prevent RSV disease requiring medical care in all infant populations studied, including those born healthy at term or preterm, or with specific health conditions that make them vulnerable to severe RSV disease. RSV disease requiring medical care included physician office, urgent care, emergency room visits and hospitalisations.¹¹

These trials form the basis of regulatory submissions that began in 2022.

Another study, the Hospitalized RSV Monoclonal Antibody Prevention (HARMONIE) trial^{2, 3}, was a large European interventional clinical trial in 250 sites and including over 8,000 infants aiming to determine the efficacy and safety of a single intramuscular (IM) dose of BEYFORTUS (<5 kg 50 mg; ≥5 kg 100 mg), compared to no intervention (standard of care), for the prevention of hospitalisations due to RSV-related LRTD in infants under 12 months of age who are not eligible to receive palivizumab.

The data from HARMONIE show that BEYFORTUS reduced the incidence of hospitalisations due to RSV-related LRTD by 82.7% (95% CI: 67.8-91.5; p<0.0001) through 180 days after administration compared to no intervention, exceeding the typical length of the five-month RSV season. The high efficacy of 83.2% previously reported in the primary analysis was sustained over the longer follow-up period with no evidence of waning protection in infants born before or during the RSV season. BEYFORTUS maintained a favorable safety profile, consistent with clinical study results. ^{2, 3}

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

References

Beyfortus® Product Prescribing Information for Singapore.
Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissières P, Royal S, Faust SN; HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.
Munro APS, Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Vassilouthis NC, Carreno M, Moreau C, Bourron P, Marcelon L, Mari K, Roberts M, Tissières P, Royal S, Faust SN; HARMONIE Study Group. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc Health. 2025 Jun;9(6):404-412. doi: 10.1016/S2352-4642(25)00102-6.
Walsh, EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. Clinics in Chest Medicine. 2017;38(1):29-36.
Karron A. Respiratory Syncytial Virus Vaccines and Monoclonal antibodies. Orenstein W, Offit P, Edwards KM, Plotkin S. Plotkin’s Vaccines, eighth edition: 998-1004. Elsevier 2023.
Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127-S132. doi:10.1067/s00223476(03)00510-9.
Zhou H, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427–1436.
Rha B, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146:e20193611.
Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9:587-595
Tam CC, et al. Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerg Infect Dis. 2020 Jul;26(7):1489-1496
Goh, D.Y.T., Goh, A., Chen, C.K. et al. Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants. World J Pediatr 21, 552–565 (2025). https://doi.org/10.1007/s12519-025-00926-2
Li Y, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022;399:92047–64.
Zhang S, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S680-687.
Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186.

http://www.sanofi.com.

Hashtag: #TogetherAgainstRSV #Sanofi #AstraZeneca #Beyfortus #RSV #RSVPrevention #InfantHealth #Pediatrics #Biopharma #HealthcareInnovation #SingaporeHealthcare #VaccineScience #PharmaNews #ClinicalTrials

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

Jackson Wang MAGICMAN 2 WORLD TOUR 2025-2026 in Macau Presented by Galaxy Macau™ heads to Galaxy Arena

MIL OSI

September 5, 2025

Source: Media Outreach

Galaxy Macau™, The World-class Luxury Integrated Resort delivers the “Most Spectacular Entertainment and Leisure Destination in the World”. Developed at an investment of HK$43 billion, the property covers 1.1 million square meters of unique entertainment and leisure attractions that are unlike anything else in Macau. Eight award-winning world-class luxury hotels provide close to 5,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel, Raffles at Galaxy Macau, Andaz Macau. Unique to Galaxy Macau, the 75,000-square-meter Grand Resort Deck features the world’s longest Skytop Adventure Rapids at 575-meters, the largest Skytop Wave Pool with waves up to 1.5-meters high and 150-meters pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz- Carlton Spa, Macau help guests relax and rejuvenate.

As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies.

Embark on a delightful and rewarding journey at Galaxy Promenade, the one-stop shopping destination boasting some of the world’s most iconic luxury brands. Be the first to get the latest limited-edition items; explore fascinating pop-ups by coveted labels and revel in fabulous shopping rewards and privileges. Our VIPs are entitled to a highly-curated experience with dedicated personal shoppers at guests’ service, and be invited to exclusive luxury brand events. A different caliber of privileges and rewards also await. Discover the joys of fashion and stand at the forefront of style and sophistication—Galaxy Promenade has everything guests need to stay ahead of the style game.

Galaxy Cinemas takes immersive movie experiences to the next level with the latest audio-visual technology, ultra-luxurious facilities and bespoke services; CHINA ROUGE, one-of-a-kind deluxe lounge that evokes the glitz and glamor of Shanghai’s golden era with entertainment in luxury and style; and Foot Hub presents the traditional art of reflexology to make you feel more relaxed and revitalized. For Authentic Macau Flavors & Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 Authentic Macau & Asian Flavors at its Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events.

Meeting, incentive and banquet groups are also well looked after with a portfolio of unique venues in Galaxy Macau and a professional service staff. Galaxy International Convention Center (GICC) is the latest addition to the Group’s ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world- class event venue featuring 40,000-square-meter of total flexible MICE, and a 16,000-seat Galaxy Arena – the largest indoor arena in Macau.

For more details, please visit www.galaxymacau.com, www.broadwaymacau.com.mo and www.galaxyicc.com.

– Published and distributed with permission of Media-Outreach.com.

PITAKA Unveils New iPhone 17 Aramid Fiber Accessories and Innovative PitaTap™ Technology at IFA 2025

MIL OSI

September 5, 2025

Source: Media Outreach

BERLIN, GERMANY – Media OutReach Newswire – 5 September 2025 – At IFA 2025, global premium mobile accessory brand PITAKA debuts its all-new iPhone 17 aramid fiber case series, showcasing cutting-edge material engineering, innovative functionality, and sustainable design.

This year, PITAKA introduces a fully upgraded aramid fiber weaving process, Fusion Weave – LightRipple, along with the world’s first application of its proprietary PitaTap™ technology on the Camera Control Button. This innovation maintains the ultra-thin, lightweight feel and exceptional touch sensitivity PITAKA is known for, while the use of seamless molding technology eliminates any post-assembly marks or rough textures—offering an unparalleled visual and tactile experience.

Thanks to these groundbreaking advancements, PITAKA has been honored with two Innovation Awards at IFA, reaffirming its leadership in the smart accessories.

iPhone 17 Aramid Fiber Case: Innovation Meets Design

Crafted with aerospace-grade aramid fiber and PITAKA’s Fusion Weave – LightRipple technology, the new case combines ultra-lightweight durability with a striking rhombic pattern that evokes dynamic, nature-inspired visuals. Fusion Weave – LightRipple offers unprecedented precision in guiding each fiber, making it PITAKA’s most advanced and technically sophisticated weaving process. The case also features scratch-resistant materials, long-lasting performance, and eco-friendly packaging, delivering both style and sustainability.

PitaTap™: Smart Touch, Seamless Control

The Ultra-Slim Case features the world’s first PitaTap™ capacitive button, seamlessly embedded beneath the aramid fiber shell. Leveraging iPhone’s capacitive sensing, it enables fast, precise touch and swipe functions—such as quick camera activation—while preserving the ultra-thin profile and the case’s signature aramid texture with highly responsive tactile performance.

Global Debut at IFA 2025: See PitaTap™ in Action

Attendees can experience the new iPhone 17 series and PitaTap™ technology hands-on. Leading tech outlets and influencers will also provide exclusive coverage of PITAKA’s Innovation Award-winning products.

Visit PITAKA at Hall 7.2B, Booth 133, from September 5–9, 10:00 AM–6:00 PM.

Hashtag: #PITAKA

The issuer is solely responsible for the content of this announcement.

– Published and distributed with permission of Media-Outreach.com.

Gang Conflict Warrant in place in Hawke’s Bay

LiveNews Publisher

September 5, 2025

Source: New Zealand Police

A Gang Conflict Warrant is now in place across Hawke’s Bay as Police respond to concerning incidents of gang violence.

Inspector Dean Clifford says the warrant gives Police special powers to search vehicles of suspected gang members, and to seize firearms, weapons, and vehicles.

It comes after two incidents in the last 48 hours believed to involve those linked to the Mongrel Mob and Black Power.

The first was a serious assault on Riverbend Road in Maraenui last night, where a firearm was reportedly discharged and two people were taken to hospital with moderate injuries.

The second was in the early hours of this morning, where Police were called to a grievous assault on Omahu Road, Hastings, where two young people sustained life-threatening injuries. Both were taken to hospital.

Inspector Clifford says an increased Police presence remains across Hawke’s Bay as we continue our enquiries into these incidents.

“I hope the Gang Conflict Warrant will do two things,” he says.

“That it reassures the public that we are using every tool at our disposal in order to keep them safe, and that it sends a clear message to those involved in this violence that we will not accept it in our community.”

ENDS

Issued by the Police Media Centre

MIL OSI

Solomon Islands – first Pacific country to scrap tax on period products – ChildFund

LiveNews Publisher

September 5, 2025

Source: ChildFund New Zealand

In a landmark step the Solomon Islands Government has become the first Pacific country to remove all taxes on menstrual products.

The historic win comes after a year of work by a voluntary team, including ChildFund’s Country Representative Hika Joseph Gone.

The group presented a formal submission to the Solomon Islands’ Ministry of Finance in 2024, calling for the removal of nearly 30% in taxes on menstrual products.

Although not officially a ChildFund project, this initiative reflects the organization’s broader commitment to promoting the rights of girls and young women, especially in areas often overlooked – like menstrual health, which often carry stigma or systemic barriers.

“It aligns with our mission to ensure every child, including every girl, has the chance to grow up safe, healthy, and empowered” says Josie Pagani, ChildFund NZ CEO.

“This is more than a policy change – it’s a declaration that menstrual health matters, and that equity, dignity, and access are values worth fighting for,” said Hika Joseph Gone, and the team.

Menstrual hygiene remains a critical but often overlooked issue in the Solomon Islands.

Stigma, lack of access to sanitary products, and poor facilities in schools have led to ongoing challenges for girls’ attendance and performance in education. The removal of taxes is expected to directly improve affordability, school participation, and health outcomes for thousands of girls and women.

ChildFund New Zealand applauds this movement and commends those advocating for it, and the Solomon Islands Government, for taking decisive action. “The Solomon Islands is setting a powerful example for the Pacific.” said Josie Pagani. “We’re incredibly proud of Hika and the team – and we hope to see other Pacific nations follow this example.”

The voluntary team included:

– Gladys Bartlett – UNICEF Ambassador and Team Leader

– Hika Joseph Gone – Country Representative for ChildFund Solomon Islands

– Mary Ramosaea

– Joel Fangalasu

– Catherine Chan.

MIL OSI

Employment Law – Minister’s intervention in ASMS’ bargaining unlawful – Union says

LiveNews Publisher

September 5, 2025

Source: Association of Salaried Medical Specialists

Prime Minister Christopher Luxon must give assurances the Minister of Health will stop breaching employment law by undermining the collective bargaining process.

Simeon Brown’s actions yesterday represent an unlawful intervention in the bargaining between Te Whatu Ora and ASMS.

Bargaining has not “broken down”. Just last week ASMS met with Health New Zealand and the Public Service Commission to discuss next steps. The day before the Minister’s letter arrived Dale Bramley spoke with ASMS to discuss further steps for bargaining.

ASMS says Brown does not understand employment law and should have received advice before making comments.

As well as being misinformed, the Minister’s proposal is disingenuous. The fundamental barrier to a settlement between Health New Zealand and the senior doctors is the failure of his government to allocate adequate funds for the safe staffing of our public health system.

If Health New Zealand had appropriate funding and staffing levels this dispute would not be happening.

The Minister’s actions are highly unusual and a direct intervention in bargaining, which is unlawful.

Collective bargaining is a process governed by law and the parties to collective bargaining have specific rights and responsibilities. The Minister seems unaware of this fact.

The Minister does not appear to understand the law. His actions in combination with the response of Health NZ Chair Lester Levy could be interpreted as undermining the bargaining process.

ASMS takes issue with the minister’s misinformation about disruptions to patient care. “In his letter the Minister claims more than 4,000 surgeries, appointments and treatments were cancelled due to the May 1 strike,” ASMS Executive Director Sarah Dalton says. “An Official Information Act Request revealed this figure to be a quarter of that at 1,037.

“A further request to discover how many appointments were made on a typical day, and cancelled, for comparison is months overdue because Health New Zealand cannot locate the data. If that is the case, where is the Minister getting his advice about cancellations from?

“It screams of recent cover up attempts we saw by HNZ to withhold data from the New Zealand Nurses Organisation about safe-staffing.”

The biggest impediment to patients accessing health care is the Government’s failure to safely staff our hospitals on a day-to-day basis. “Every day theatres and clinics are cancelled due to staffing gaps.

“At the same time Health NZ has paid out more than $200M in the past 12 months on temporary staff (locums) and additional duties payments for existing staff to cover the work of missing colleagues.

“It makes no sense to pay ever increasing locum rates while clamping down on improved terms and conditions that will attract and retain desperately needed specialist doctors and dentists – especially in smaller and rural hospitals.”

ASMS lodged a revised claim with Health New Zealand during facilitated bargaining with a view to reach a compromise.

“We are happy to get back around the table with HNZ,” Dalton says. “They tell us they have a shared commitment to see improved staffing levels around the country. We need to see evidence of that.”

MIL OSI

Federated Farmers push for national pest strategy

LiveNews Publisher

September 5, 2025

Source: Federated Farmers

With rising numbers of feral animals hammering farm pasture, fences and native bush, Federated Farmers is calling for a national pest strategy.

“Farmers are constantly reporting bigger mobs of feral deer, wild pigs eating lambs, and huge flocks of Canada geese and ducks fouling farmland and waterways,” Federated Farmers meat and wool chair Richard Dawkins says.

Federated Farmers has asked Parliament’s Primary Production Committee to set up a joint agency briefing to clarify the scale of New Zealand’s pest problem, what it means for climate change, and where the current governance framework is falling short.

“We need action that covers all pest species, all land tenures, and brings every stakeholder into one coordinated effort.”

Dawkins says the current fragmented approach, with responsibility divided by land tenure and function, is holding back progress.

“One example – the Department of Conservation (DOC) is tasked to manage pests on public conservation land, but its statutory responsibilities don’t extend to private land.

“This leads to pests moving freely across public estate boundaries and imposing massive costs on farmers.”

Regional councils, Biosecurity New Zealand (MPI), the Environmental Protection Authority (EPA) and OSPRI (targeting TB vectors – mainly possums), all have roles.

“Responsibility is split across these multiple agencies, with no central leadership or clear lines of accountability,” Dawkins says.

“The result is gaps, inefficiencies, and inconsistent coverage – and productive land pays the price.”

He says farmers are particularly angry that some forestry companies and investors – particularly carbon forestry speculators who blanket the land in pines and walk away – leave it to farmer neighbours to suffer the pest consequences.

“It is hugely damaging and only appears to be getting worse.”

There’s also uncertainty about which agency and Minister are responsible for pest pressures that primarily affect the productive sector, especially outside of conservation land.

Similar to DOC’s different priorities, forest owners often invest in pest control until trees are no longer vulnerable to browsing damage.

“The forests become habitat for pest species. These then travel across boundaries and wreak havoc.”

Last year’s inaugural Federated Farmers National Pest Survey of more than 700 farmers left no room for doubt on the scale of the problem.

One finding was that, at a conservative estimate, farmers are spending almost $74 million on pest control each year, and shouldering another $139 million a year in costs from damaged fencing, pasture consumed and loss of trees.

“Our survey was a great start, but it’s past time that agencies worked together to build a national pest inventory for an accurate picture of where we’re at,” Dawkins says.

“There’s no consolidated national dataset to confirm or quantify just how fast pest animal populations are rising, and what regions are worst affected.

“There’s truth in the saying ‘you can’t manage what you don’t measure’.

“While there’s no doubt that is important, we also need action. We need lead in the air, we need to eradicate these problem species.

“It’s not overly productive spending most of our resources on monitoring and planning. It’s also up to every landowner to play their part.”

Climate change and emissions factors are another reason Federated Farmers wants action.

“Our food producing sector is being asked to make big cuts in emissions, but what about the methane and nitrous oxide coming from pests like deer, goats and pigs?

“That’s surely having a serious impact on New Zealand’s greenhouse gas inventory, especially when you consider that feral animals are also smashing our native forests, regenerating scrub and grasslands.

“We need data on how pests are affecting the carbon dioxide sequestration ability of this vegetation.”

The potential for greater sequestration across DOC-managed native bush is considerable.

“Instead of replacing productive sheep and beef farms in monoculture carbon forestry, we should be looking at other opportunities.

“The eight million hectare DOC estate surely presents better opportunities for improving and measuring carbon capture.”

Wilding pines and other weeds also need to be part of cross-agency campaigns, Dawkins says.

“Federated Farmers has consistently warned that we’re losing the battle on wilding pines – an ecological crisis is unfolding on that front alone.

“We have presented cost-effective alternatives such as streamlining the grazing consent process, reintroducing crown pastoral leases, tactical burning and the use of new technology and techniques for wilding control.

“We need a pest animal and weed strategy, and cross-party support for long-term action.

“As time goes on, these issues only become larger and more expensive. The time for action is now.”

MIL OSI

1...484950...1,054 Page 49 of 1,054